Numerical Models and Methods of Atmospheric Parameters Originating in the Formation of the Earth’s Climatic Cycle

Atmospheric models are physical equations based on the ideal gas law. Applied to the atmosphere, this law yields equations for water, vapor (gas), ice, air, humidity, dryness, fire, and heat, thus defining the model of key atmospheric parameters. The distribution of these parameters across the entire planet Earth is the origin of the formation of the climatic cycle, which is a normal climatic variation. To do this, the Earth is divided into eight (8) parts according to the number of key parameters to be defined in a physical representation of the model. Following this distribution, numerical models calculate the constants for the formation of water, vapor, ice, dryness, thermal energy (fire), heat, air, and humidity. These models vary in complexity depending on the indirect trigonometric direction and simplicity in the sum of neighboring models. Note that the constants obtained from the equations yield 275.156˚K (2.006˚C) for water, 273.1596˚K (0.00963˚C) for vapor, 273.1633˚K (0.0133˚C) for ice, 0.00365 in/s for atmospheric dryness, 1.996 in2/s for humidity, 2.993 in2/s for air, 1 J for thermal energy of fire, and 0.9963 J for heat. In summary, this study aims to define the main parameters and natural phenomena contributing to the modification of planetary climate. .

Meiotic nuclear divisions 1 suppresses the proliferation and invasion of pancreatic cancer cells via regulating H2A.X variant histone

Introduction:Among all malignant tumors of the digestive system,pancreatic carcinoma exhibits the highest mortality rate.Currently,prevention and effective treatment are urgent issues that need to be addressed.Methods:The study focused on meiotic nuclear divisions 1(MND1),integrating data from the Gene Expression Profiling Interactive Analysis(GEPIA)database with prognostic survival analysis.Simultaneously,experiments at cellular level were employed to demonstrate the effect of MND1 on the proliferation and migration of PC.The small-molecule inhibitor of MND1 was used to suppress the migration of PC cells by knocking down MND1 using small interfering RNA(siRNA)in Patu-8988 and Panc1 cell lines.Results:The results of Cell Counting Kit-8 indicated that the suppression of MND1 resulted in a decrease in cell proliferation.Wound healing and Transwell assays revealed that MND1 knockdown reduced cell migration and invasion.Flow cytometry revealed that inhibiting MND1 hindered the cell cycle.Furthermore,MND1 could stimulate the proliferation,migration,and invasion of Patu-8988 and Panc1 cells by increasing the expression of MND1.Notably,MND1 had a positive effect on H2AFX expression in PC cells.Elevated MND1 expression suggests the low overall survival rate of individuals diagnosed with PC.Conclusion:These findings suggest that MND1 has the potential to be a gene with the ability to accurately diagnose and treat PC.

Dexamethasone suppresses DU145 cell proliferation and cell cycle through inhibition of the extracellular signal-regulated kinase 1 /2 pathway and cyclin D1 expression

Aim： To determine the mechanisms of glucocorticoids in inhibiting advanced prostate cancer growth. Methods： The cell proliferation and cell cycle of prostate cancer DU145 cells following dexamethasone treatment were determined by proliferation assay and fluorescence-activated cell sorter. Western blot analysis was carried out to evaluate the effects of dexamethasone on phosphorylation of extracellular signal-regulated kinase （ERK）1/2 and expression of cyclin D1 in DU145 cells with or without glucocorticoid receptor （GR） antagonist RU486. Reverse transcription- polymerase chain reaction verified the expression of GR mRNA in DU145 cells. Results： Dexamethasone significantly inhibited DU 145 cell proliferation at the G0/G1 phase. Westem blot analysis showed a dramatic reduction of ERK1/2 activity and cyclin D1 expression in dexamethasone-treated cells. The decreased phosphorylation of ERK1/2 in dexamethasone-treated cells was attenuated by GR blockade. Additionally, the effects of dexamethasone in inhibiting cyclin D1 expression were altered by GR blockade. Conclusion： Dexamethasone suppresses DU145 cell proliferation and cell cycle, and the underlying mechanisms are through the inhibition of phosphorylation of ERK1/2 and cyclin D1 expression. The inhibition of ERK1/2 phosphorylation and cyclin D1 expression is attenuated by GR blockade, suggesting that GR regulates ERK1/2 and cyclin D1 pathways. These observations suggest that dexamethasone has a potential clinical application in prostate cancer therapy.

Hydrate-based carbon dioxide capture from simulated integrated gasification combined cycle gas

The equilibrium hydrate formation conditions for CO2/H2 gas mixtures with different CO2 concentrations in 0.29 mol% TBAB aqueous solution are firstly measured.The results illustrate that the equilibrium hydrate formation pressure increases remarkably with the decrease of CO2 concentration in the gas mixture.Based on the phase equilibrium data,a three stages hydrate CO2 separation from integrated gasification combined cycle （IGCC） synthesis gas is investigated.Because the separation efficiency is quite low for the third hydrate separation,a hybrid CO2 separation process of two hydrate stages in conjunction with one chemical absorption process （absorption with MEA） is proposed and studied.The experimental results show H2 concentration in the final residual gas released from the three stages hydrate CO2 separation process was approximately 95.0 mol% while that released from the hybrid CO2 separation process was approximately 99.4 mol%.Thus,the hybrid process is possible to be a promising technology for the industrial application in the future.

Intrinsic apoptotic pathway and G2/M cell cycle arrest involved in tubeimoside I-induced EC109 cell death

Objective： Squamous esophageal carcinoma is highly prevalent in developing countries, especially in China. Tu Bei Mu （TBM）, a traditional folk medicine, has been used to treat esophageal squamous cell carcinoma （ESCC） for a long term. tubeimoside I （TBMS1） is the main component of TBM, exhibiting great anticancer potential. In this study, we investigated the mechanism of TBMS1 cytotoxic effect on EC109 cells. Methods： Comparative nuclear proteomic approach was applied in the current study and we identified several altered protein spots. Further biochemical studies were carried out to detect the mitochondrial membrane potential, cell cycle and corresponding proteins＇ expression and location. Results： Subcellular proteomic study in the nucleus from EC109 cells revealed that altered proteins were associated with mitochondrial function and cell proliferation. Further biochemical studies showed that TBMSl-induced molecular events were related to mitochondria-induced intrinsic apoptosis and P21-cyclin B 1/cdc2 complex-related G2/M cell cycle arrest. Conclusions： Considering the conventional application of TBM in esophageal cancer, TBMS1 therefore may have a great potential as a chemotherapeutic drug candidate for ESCC.

6-OHDA Induces Cycle Reentry and Apoptosis of PC12 Cells through Activation of ERK1/2 Signaling Pathway

This study investigated the effect and mechanism of cell cycle reentry induced by 6-hydrodopamine （6-OHDA） in PC12 cells. By using neural differentiated PC12 cells treated with 6-OHDA, the apoptosis model of dopaminergic neurons was established. Cell viability was measured by MTT. Cell apoptosis and the distribution of cell cycle were assessed by flow cytometry. Western blot was used to detect the activation of extracellular regulator kinasel/2 （ERK1/2） pathway and the phosphorylation of retinoblastoma protein （RB）. Our results showed that after PC12 cells were treated wtih 6-OHDA, the viability of PC12 cells was declined in a concentration-dependent manner. Flow cytornetry revealed that 6-OHDA could increase the apoptosis ratio of PC12 cells in a time-dependent manner. The percentage of ceils in G0/G1 phase of cell cycle was decreased and that in S phase and G2/M phase increased. Simultaneously, ERK1/2 pathway was activated and phosphorylated RB increased. It was concluded that 6-OHDA could induce cell cycle reentry of dopaminergic neurons through the activation of ERK1/2 pathway and RB phosphorylation. The aberrant cell cycle reentry contributes to the apoptosis of dopaminergic neurons.

Upregulation of miR-34c after silencing E2F transcription factor 1 inhibits paclitaxel combined with cisplatin resistance in gastric cancer cells

BACKGROUND MicroRNA 34c(miR-34c)has been reported to be associated with malignant types of cancer,however,it remains unknown whether miR-34c is involved in chemoresistance in gastric cancer(GC).AIM To investigate the effect of miR-34c and its upstream transcription factor E2F1 on paclitaxel combined with cisplatin resistance in GC cells.METHODS Paired GC tissues and adjacent normal tissues were randomly sampled from 74 GC patients.miR-34c and E2F1 were detected by real-time quantitative PCR(qPCR)and Western blot.In addition,the drug resistance of GC cells to paclitaxel and cisplatin was induced by concentration gradient increasing methods,and changes in miR-34c and E2F1 during this process were measured.Furthermore,E2F1 and miR-34c overexpression or underexpression vectors were constructed and transfected into drug-resistant GC cells.MTT was employed to test the sensitivity of cells to paclitaxel combined with cisplatin,qPCR was adopted to detect the expression of miR-34c,Western blot was applied to detect the expression levels of E2F1,drug resistance-related proteins and apoptosis-related proteins,and flow cytometry was used for the determination of cell apoptosis and cell cycle status.RESULTS E2F1 was overexpressed while miR-34c was underexpressed in GC.After inducing GC cells to be resistant to paclitaxel and cisplatin,E2F1 expression increased while miR-34c expression decreased.Both silencing E2F1 and overexpressing miR-34c could increase the sensitivity of drug-resistant GC cells to paclitaxel combined with cisplatin,promote cell apoptosis and inhibit cell proliferation.Among which,silencing E2F1 could reduce the expression of drug resistance-related proteins and apoptosis-related proteins,while over-expression of miR-34c could upregulate the expression of apoptosis-related proteins without affecting the expression of MDR-1,MRP and other drug resistance-related proteins.Rescue experiments demonstrated that inhibiting miR-34c could significantly weaken the sensitization of drug resistant cells,and Si E2F1 to paclitaxel combined with cisplatin.CONCLUSION E2F1 inhibits miR-34c to promote the proliferation of GC cells and enhance the resistance to paclitaxel combined with cisplatin,and silencing E2F1 is conducive to improving the efficacy of paclitaxel combined with cisplatin in GC cells.

Vitamin C Inhibits Benzo[a]pyrene-Induced Cell Cycle Changes Partly via Cyclin D1/E2F Pathway in Human Embryo Lung Fibroblasts

Objective To study the molecular mechanism of the inhibitory effects of vitamin C on benzo[a]pyrene （B[a]P）-induced changes of cell cycle in human embryo lung fibroblast （HELF） cells. Methods The stable transfectants, HELF transfected with antisense cyclin D1 and antisense CDK4, were established. Cells were cultured and pretreated with vitamin C before stimulation with B[a]P for 24 h. The expression levels of cyclin DI, CDK4, E2FI, and E2F4 were determined by Western blot. Flow cytometric analysis was employed to detect the distributions of cell cycle. Results B[a]P significantly elevated the expression levels of cyclin D 1, E2F1, and E2F4 in HELF cells. Vitamin C decreased the expression levels of cyclin D 1, E2F1, and E2F4 in B [a]P-stimulated HELF cells. Dose-dependent relationships were not found between the different concentrations of vitamin C （10, 100, 500, 1000, and 5000 lamol/L） and the expression levels of cyclin D 1, E2F1, and E2F4 in HELF cells. The expression levels of cyclin D1, E2FI, and E2F4 in B[a]P-treated transfectants were lower than those in B[a]P-treated HELF cells. The expression levels of cyclin DI and E2F4 treated with vitamin C and antisense cyclin D1 were decreased compared with those treated with antisense cyclin DI alone. The effects of vitamin C combined with antisense CDK4 on the expression levels of cyclin DI and E2FI/E2F4 were similar to those of antisense CDK4 alone. B[a]P progressed HELF cells from GI to S phase. Both vitamin C and antisense cyclin DI suppressed the changes of cell cycle progressed by B[a]P. However, antisense CDK4 did not attenuate the above changes. Vitamin C combined with antisense CDK4 markedly suppressed B[a]P-induced changes of cell cycle as compared with antisense CDK4. But the inhibitory effects of vitamin C combined with antisense cyclin DI on B[a]P-induced changes of cell cycle were similar to those of vitamin C alone or antisense cyclin DI alone. Conclusions B[a]P progressed HELF cells from G1 to S phase via intracellular signaling pathway of cyclin D I/E2F. Vitamin C may modulate this signaling pathway to protect cells from injury caused by B[a]P.

PD-1/PD-L1抑制剂联合抗血管内皮生长因子药物免疫治疗晚期肝癌的研究进展

肝细胞癌(hepatocellular carcinoma,HCC)是全球高发的恶性肿瘤。程序性死亡蛋白-1(programmed death protein-1,PD-1)/程序性死亡蛋白配体-1(programmed death protein ligand-1,PD-L1)抑制剂可通过阻断T细胞负调节信号,抑制肿瘤细胞免疫逃逸途径,重新激活抗肿瘤免疫应答过程,成为晚期HCC治疗的新手段。然而,长期临床结果显示,采用PD-1/PD-L1抑制剂单药治疗晚期HCC的病人仍存在较高的复发率和转移率。免疫联合疗法是目前针对晚期HCC患者的新的治疗策略,其中PD-1/PD-L1抑制剂联合抗血管内皮生长因子(vascular endothelial growth factor,VEGF)药物在晚期HCC治疗中显示出了良好的疗效和安全性。PD-1/PD-L1抑制剂联合抗VEGF药物可通过参与癌症免疫循环途径抑制肝癌细胞的生长。该文就PD-1/PD-L1抑制剂联合抗VEGF药物在晚期HCC治疗中的临床研究作一综述。

Metabolic and cardiovascular benefits with combination therapy of SGLT-2 inhibitors and GLP-1 receptor agonists in type 2 diabetes

Both GLP-1 receptor agonists(GLP-1RA)and SGLT-2 inhibitors(SGLT-2I)are newer classes of anti-diabetic agents that lower HbA1c moderately and decrease body weight and systolic blood pressure(SBP)modestly.Combination therapy with GLP-1RA plus SGLT-2I have shown a greater reduction in HbA1c,body weight,and SBP compared to either agent alone without any significant increase in hypoglycemia or other side effects.Since several agents from each class of these drugs have shown an improvement in cardiovascular(CV)and renal outcomes in their respective cardiovascular outcome trials(CVOT),combination therapy is theoretically expected to have additional CV and renal benefits.In this comprehensive opinion review,we found HbA1c lowering with GLP-1RA plus SGLT-2I to be less than additive compared to the sum of HbA1c lowering with either agent alone,although body weight lowering was nearly additive and the SBP lowering was more than additive.Our additional meta-analysis of CV outcomes with GLP1RA plus SGLT-2I combination therapy from the pooled data of five CVOT found a similar reduction in three-point major adverse cardiovascular events compared to GLP-1RA or SGLT-2I alone,against placebo.Interestingly,a greater benefit in reduction of heart failure hospitalization with GLP-1RA plus SGLT-2I combination therapy was noted in the pooled meta-analysis of two randomized controlled trials.Future adequately powered trials can confirm whether additional CV or renal benefit is truly exerted by GLP-1RA plus SGLT-2I combination therapy.

Different Patterns of Cyclin D1/CDK4-E2F-1/4 Pathways in Human Embryo Lung Fibroblasts Treated by Benzo[a]pyrene at Different Doses

Objective To investigate the roles of the cyclin D1/CDK4 and E2F-1/4 pathways and compare their work patterns in cell cycle changes induced by different doses of B[a]E Methods Human embryo lung fibroblasts （HELFs） were treated with 2 μmol/L or 100 μmol/L B[a]P which were provided with some characteristics of transformed cells （T-HELFs）. Cyclin D l, CDK4 and E2F-1/4 expressions were determined by Western blotting. Flow cytometry was used to detect the distribution of cell cycle. Results After B[a]P treatment, the proportion of the first gap （G 1） phase cells decreased. CDK4 and E2F-4 expression did not change significantly. In 2 μmol/L treated cells, a marked overexpression of cyclin D1 and E2F-1 was observed. However, in T-HELFs overexpression was limited to cyclin D1 only, and no overexpression of E2F-1 was observed. The decreases of G1 phase in response to B[a]P treatment were blocked in antisense cyclin D1 and antisense CDK4 transfected HELFs （A-D1 and A-K4） and T-HELFs （T-A-D1 and T-A-K4）. After 2 μmol/L B[a]P treatment, overexpression of E2F-1 was attenuated in A-D1, and E2F-4 expression was decreased significantly in A-K4. In T-A-D1 and T-A-K4, E2F-4 expression was increased significantly, compared with T-HELFs. The E2F-1 expression remained unchanged in T-A-D1 and T-A-K4. Condusions Cyclin DI/CDK4-E2F-1/4 pathways work in different patterns in response to low dose and high dose B[a]P treatment. In HELFs treated with 2 μmol/L B[a]P, cyclin D1 positively regulates the E2F-1 expression while CDK4 negatively regulates the E2F-4 expression; however, in HELFs treated with 100 μmol/L B[a]P, both cyclin D1 and CDK4 negatively regulate the E2F-4 expression.

Comparative Evaluation of the Efficacy of the Bimatoprost 0.03%, Brimonidine 0.2%, Brinzolamide 1%, Dorzolamide 2%, and Travoprost 0.004%/Timolol 0.5%-Fixed Combinations in Patients Affected by Open-Angle Glaucoma

Purpose: This is a retrospective, comparative, head-to-head, not commissioned study about the efficacy of bimato-prost 0.03%, brimonidine 0.2%, brinzolamide 1%, dorzolamide 2%, and travoprost 0.004%/timolol 0.5%-fixed combinations in patients affected by na?ve open-angle glaucoma and IOP > 25 mmHg. Patients and Methods: Files from 70 patients (35 M, 35 F, mean age 69.52 y, S.D. 11.56, range: 37-87y) in our Glaucoma Service were retrospectively analyzed as long as 12 months. Every subgroup, including 14 age- and sex-matched patients, was allocated to 1 of the 5 groups of the fixed combinations monotherapy. Data recorded after 3 months follow-up were statistically analyzed by descriptive and ANOVA statistics as percentage of IOP reduction from baseline. Results: All the fixed combinations were effective in lowering IOP. The mean percentage reduction was: brimonidine/timolol 43.57%, dorzolamide/timolol 37.67%, bimatoprost/timolol 35.60%, travoprost/timolol 33.25% and brinzolamide/timolol 23.0%. The brimonidine/timolol fixed combination showed to be statistically significant more effective only than brinzolamide/timolol fixed combination (p = 0.001). Setting the α error to 5%, the power of the study is 26%, phi: 0.842. Discussion: In all this cohort of patients the target IOP was successfully achieved. All the fixed combinations used in this study had a very good profile of efficacy. Brimonidine, dorzolamide, bimatoprost and travoprost/timolol fixed combinations statistically significantly reduced the percentage of IOP from baseline (p = 0.001) more than brinzolamide/timolol fixed combination.

二甲双胍联合GLP-1受体激动剂治疗2型糖尿病合并心血管疾病的药理机制研究

目的 探讨研究二甲双胍联合GLP-1受体激动剂治疗2型糖尿病合并心血管疾病的药理机制。方法 选取2021年5月~2022年12月收治并确诊为2型糖尿病合并心血管疾病的患者90例,用随机数字表法分为研究组与对照组,每组各45例。两组患者均给予常规运动及饮食控制干预,对照组患者给予二甲双胍治疗,研究组患者给予二甲双胍联合GLP-1受体激动剂治疗,比较两组患者的心功能、血糖、血脂指标及不良反应的发生情况。结果 治疗后研究组的左室舒张末期内径(LVEDd)指标降低较对照组更为明显,研究组的左室射血分数(LVEF)、舒张早期最大峰值速度/舒张晚期最大峰值速度(E/A)指标高于对照组(P <0.05)。治疗后研究组患者的测糖化血红蛋白(HbA1c)、空腹血糖(FPG)、餐后2 h血糖(2 hPG)指标低于对照组(P <0.05)。治疗后研究组患者甘油三酯(TG)、总胆固醇(TC)及低密度脂蛋白胆固醇(LDL-C)指标低于对照组,高密度脂蛋白胆固醇(HDL-C)高于对照组(P <0.05)。研究组不良反应发生率为6.67%,较对照组的13.33%更低,但差异无统计学意义(P> 0.05)。结论 二甲双胍联合GLP-1受体激动剂治疗2型糖尿病合并心血管疾病的临床疗效较好,安全性较高,有效调节患者的血糖血脂水平,改善心功能状态,保护心血管系统,提升患者生存质量。

2-甲氧基雌二醇对SKM-1细胞凋亡中bcl-2/bax表达的影响

目的探讨2-甲氧基雌二醇（2-ME）对骨髓增生异常综合征SKM-1细胞凋亡过程中bcl-2/bax表达的影响。方法 2-ME与SKM-1细胞共同培养,流式细胞术分析细胞凋亡率和细胞周期;RT-PCR技术检测bcl-2和bax mRNA表达。结果 1~8μmol/L 2-ME作用后,SKM-1细胞凋亡率上升呈剂量依赖性;细胞被阻滞于G2/M期;细胞bcl-2 mRNA表达量下调,bax mRNA表达量上调。结论 2-ME诱导SKM-1细胞凋亡与细胞G2/M期阻滞和bcl-2/bax比率下降有关。

细胞外信号调节激酶1/2的阻断剂PD98059对小鼠淋巴细胞增殖的影响

目的探讨细胞外信号调节激酶1/2(ERK1/2)信号通路的特异性阻断剂PD98059对小鼠淋巴细胞体外增殖的影响。方法分离小鼠淋巴结细胞,藉羧基荧光素乙酰乙酸(CFDA-SE)染色,用多克隆刺激剂刀豆A蛋白(ConA)或者佛波醇酯(PDB)加离子霉素(Ion)刺激,以流式细胞术分析PD98059对淋巴细胞增殖的影响;利用碘化丙锭(PI)染色分析PD98059对细胞周期的影响。结果CFDA-SE染色分析显示,当浓度为5、10、20、30、40μmol/L时,PD98059对ConA诱导的淋巴细胞增殖具有明显的抑制作用,并呈现明显的剂量依赖关系(r=0.985,P<0.01)。选择最佳浓度30μmol/L的PD98059,观察其对不同时间淋巴细胞增殖的影响,结果发现,随着时间的延长,PD98059对淋巴细胞增殖的抑制作用明显降低(P<0.01),但抑制率随时间的延长而明显升高。细胞周期分析进一步表明,PD98059可阻止ConA刺激的淋巴细胞进入S期和G2/M期,而亚二倍体峰变化并不明显。PD98059对PDB+Ion刺激的淋巴细胞细胞周期的影响与ConA刺激相似,不同的是S期和G2/M期的变化较ConA的作用更明显。结论PD98059对小鼠淋巴细胞的增殖有明显地抑制作用,并可阻止其进入S期和G2/M期,提示ERK1/2信号通路的活化在淋巴细胞增殖中起重要作用。

黄芪甲苷和三七的三种有效成分配伍对小鼠脑缺血/再灌注后氧化应激和Nrf2/HO-1途径的影响

目的研究黄芪的主要有效成分黄芪甲苷分别与三七的有效成分人参皂苷Rg1、人参皂苷Rb1、三七皂苷R1配伍对小鼠脑缺血/再灌注后氧化应激和核转录因子E2相关因子2(nuclear factor-erythroid 2 related factor 2,Nrf2)/血红素加氧酶(heme oxygenase,HO)-1途径的影响。方法C57BL/6小鼠随机分组,连续给药3 d,末次给药1 h后,结扎双侧颈总动脉造成脑缺血20 min,再灌注24 h。测定脑组织丙二醛(malonyldialdehyde,MDA)、一氧化氮(nitric oxide,NO)、超氧化物歧化酶(superoxide dismutase,SOD)、谷胱甘肽(glutathione,GSH),HO-1mRNA表达,脑组织胞核、胞质Nrf2和全细胞HO-1蛋白表达。结果①脑缺血/再灌注后,脑组织MDA、NO含量明显升高,SOD活性和GSH含量明显降低。黄芪甲苷可降低脑组织MDA、NO含量,人参皂苷Rg1能降低脑组织NO含量。黄芪甲苷+人参皂苷Rg1、黄芪甲苷+人参皂苷Rb1和黄芪甲苷+三七皂苷R1均能明显降低脑组织MDA和NO含量,且黄芪甲苷与人参皂苷Rb1、三七皂苷R1配伍的效应大于人参皂苷Rb1单用和三七皂苷R1单用。②脑缺血/再灌注后,脑组织胞核和胞质中Nrf2蛋白含量及核转位率升高,同时HO-1mRNA和蛋白表达增强。各给药组能不同程度地降低胞质Nrf2蛋白含量,升高胞核Nrf2含量,使Nrf2核转位率升高,且黄芪甲苷+人参皂苷Rg1、黄芪甲苷+人参皂苷Rb1、黄芪甲苷+三七皂苷R1的作用强于各有效成分单用。黄芪甲苷、人参皂苷Rg1、黄芪甲苷+人参皂苷Rg1、黄芪甲苷+人参皂苷Rb1、黄芪甲苷+三七皂苷R1可使脑组织HO-1mRNA和蛋白表达明显增加,黄芪甲苷+人参皂苷Rg1、黄芪甲苷+人参皂苷Rb1、黄芪甲苷+三七皂苷R1脑组织HO-1mRNA和蛋白的增加明显高于各有效成分单用。且黄芪甲苷+人参皂苷Rg1升高胞核Nrf2蛋白、提高Nrf2核转位率的作用强于黄芪甲苷+人参皂苷Rb1,增加HO-1基因和蛋白表达的作用强于黄芪甲苷+人参皂苷Rb1和黄芪甲苷+三七皂苷R1。结论黄芪甲苷分别与三七的3种有效成分配伍可增强其抗脑缺血/再灌注后氧化应激损伤的作用,其作用机制可能与激活Nrf2/HO-1信号途径,促进Nrf2合成和核转位,从而促进下游抗氧化基因HO-1等的表达有关,黄芪甲苷与人参皂苷Rg1配伍的效应更为明显。

1α,25(OH)_2D_3通过阻滞细胞周期抑制胃癌细胞系增殖

目的研究1α,25(OH)2D3对胃癌细胞增殖和细胞周期的影响,并探讨其相关的作用机制。方法 BGC-823和SGC-7901胃癌细胞系分别给予终浓度为1×10-10～1×10-7mol/L的1α,25(OH)2D3处理72 h,用MTT法检测细胞抑制率;用流式细胞仪检测细胞周期;用RT-qPCR技术检测细胞周期相关基因P21、cyclin D1、cyclin E1和CDK6 mRNA表达。结果 1α,25(OH)2D3对胃癌细胞的增殖抑制率具有浓度依赖性,1α,25(OH)2D3干预导致BGC-823和SGC-7901细胞系G1期细胞比例升高,S期细胞比例降低(P<0.05);1α,25(OH)2D3干预后,BGC-823和SGC-7901胃癌细胞P21 mRNA表达升高(P<0.01),而cyclin D1、cyclin E1和CDK6 mRNA表达降低(P<0.01)。结论 1α,25(OH)2D3抑制胃癌细胞增殖,诱导细胞周期阻滞,可能与上调P21,下调cyclin D1、cyclin E1和CDK6的表达有关。

加味参附姜苓汤对围月经期咳嗽变异性哮喘患者血清MMP-2、MMP-9及TIMP-1表达的影响

目的研究加味参附姜苓汤对围月经期咳嗽变异性哮喘患者血清金属基质蛋白酶-2(MMP-2)、金属基质蛋白酶-9(MMP-9)及金属基质蛋白酶抑制剂-1(TIMP-1)表达的影响,探讨其治疗围月经期咳嗽变异性哮喘的作用机制。方法将围月经期咳嗽变异性哮喘患者80例,随机分为治疗组和对照组各40例。治疗组服用加味参附姜苓汤治疗,对照组口服氨茶碱缓释片联合酮体芬片治疗,疗程3个月。观察两组疗效及治疗前后血清MMP-2、MMP-9及TIMP-1表达变化。结果治疗组总有效率为90.0%,对照组为72.5%,治疗组疗效优于对照组(P<0.05)。治疗后两组血清MMP-2、MMP-9及TIMP-1表达水平显著降低(P<0.05,P<0.01),且治疗组降低较对照组显著(P<0.05,P<0.01)。结论加味参附姜苓汤对围月经期咳嗽变异性哮喘具有较好的疗效,其可能通过下调患者血清MMP-2、MMP-9及TIMP-1表达而发挥治疗作用。

拟面积多波长数据线性双组合解析萘、1-萘酚和2-萘酚同步荧光光谱的研究

本文研究了△λ(λ_(em)—λ_(ex))为130nm和pH12.0条件下,萘、1—萘酚和2—萘酚混合物的同步荧光光谱,获三者同步荧光峰信息,且萘被完全分辨.另外,提出用拟面积多波长数据线性双组合计算解析重叠的1—萘酚和2—萘酚同步荧光光谱,解析结果的精密度、组份间浓度比范围均较多波长线性回归、双峰倍增配平和一阶导数解析混合物同步荧光光谱结果为优.

1,2,4-三氯苯环境污染修复技术研究进展

综述了物理修复、化学修复、微生物修复及联合修复等几种主要的1,2,4-三氯苯(1,2,4-TCB)环境污染修复技术的研究进展。阐述了各种修复方法的反应原理、修复条件和效果,对比了各种修复方法的优缺点。提出今后的研究方向:解决物理吸附法修复1,2,4-TCB污染后的吸附剂的后续处理问题;优化化学降解1,2,4-TCB的工艺条件,避免二次污染,进行现场试验,实现工程应用;分离、培育1,2,4-TCB的优势降解菌种;深入研究联合修复技术的降解机理,实现1,2,4-TCB的高效、彻底降解。